In a report released today, Carl Byrnes from Northland Securities reiterated a Buy rating on Zogenix (ZGNX), with a price target of $65.00. The company’s shares closed last Thursday at $17.53, close to its 52-week low of $16.73.
According to TipRanks.com, Byrnes has 0 stars on 0-5 stars ranking scale with an average return of -10.9% and a 32.5% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Oncternal Therapeutics, Aridis Pharmaceuticals, and Adamas Pharmaceuticals.
Zogenix has an analyst consensus of Strong Buy, with a price target consensus of $52.50, representing a 201.9% upside. In a report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $55.00 price target.
See today’s analyst top recommended stocks >>
Zogenix’s market cap is currently $978.4M and has a P/E ratio of -4.50. The company has a Price to Book ratio of 3.68.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical company. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.
Read More on ZGNX:
